为您找到相关结果约112个

你是不是要搜索 期刊Inebilizumab 点击跳转

Inebilizumab: First Approval

Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder

Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder

Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism

Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis ofaquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for > 4 years in the N-MOmentum

Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder

MULTIDIMENSIONAL EVALUATION OF INEBILIZUMAB IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER

Pharmacodynamic modelling and exposure-response assessment of inebilizumab in subjects with neuromyelitis

The Safety And Efficacy Of Inebilizumab In Those With Previous Rituximab Exposure

Immunoglobulin kinetics and infection risk after long-term inebilizumab treatment for NMOSD

Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial

Immunoglobulin Kinetics And Infection Risk After Long-Term Inebilizumab Treatment For NMOSD

AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica

为您找到相关结果约112个

共112条页码: 1/8页15条/页